Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MDX2003 |
| Synonyms | |
| Therapy Description |
MDX2003 is a tetraspecific T-cell engager targeting CD19 and MS4A1 (CD20) on B-cells and CD3 and CD28 on T-cells, which potentially induces T-cell activation and inhibition of tumor growth (Blood (2025) 146 (Supplement 1): 3311). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MDX2003 | MDX-2003|MDX 2003 | CD19 Antibody 22 CD20 Antibody 28 CD28 Antibody 13 CD3 Antibody 123 | MDX2003 is a tetraspecific T-cell engager targeting CD19 and MS4A1 (CD20) on B-cells and CD3 and CD28 on T-cells, which potentially induces T-cell activation and inhibition of tumor growth (Blood (2025) 146 (Supplement 1): 3311). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07249905 | Phase Ib/II | MDX2003 | Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma | Recruiting | AUS | 0 |